Milestone Pharmaceuticals (MIST) Competitors $1.89 +0.04 (+2.16%) (As of 02:22 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MIST vs. IGMS, CYRX, TSHA, CTNM, RGNX, GHRS, YMAB, SANA, DSGN, and KMDAShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include IGM Biosciences (IGMS), Cryoport (CYRX), Taysha Gene Therapies (TSHA), Contineum Therapeutics (CTNM), REGENXBIO (RGNX), GH Research (GHRS), Y-mAbs Therapeutics (YMAB), Sana Biotechnology (SANA), Design Therapeutics (DSGN), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. IGM Biosciences Cryoport Taysha Gene Therapies Contineum Therapeutics REGENXBIO GH Research Y-mAbs Therapeutics Sana Biotechnology Design Therapeutics Kamada Milestone Pharmaceuticals (NASDAQ:MIST) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations. Do insiders & institutionals have more ownership in MIST or IGMS? 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 9.9% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate MIST or IGMS? Milestone Pharmaceuticals presently has a consensus price target of $12.00, suggesting a potential upside of 548.65%. IGM Biosciences has a consensus price target of $17.75, suggesting a potential upside of 173.92%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than IGM Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00IGM Biosciences 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer MIST or IGMS? Milestone Pharmaceuticals received 9 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 69.23% of users gave Milestone Pharmaceuticals an outperform vote while only 50.70% of users gave IGM Biosciences an outperform vote. CompanyUnderperformOutperformMilestone PharmaceuticalsOutperform Votes8169.23% Underperform Votes3630.77% IGM BiosciencesOutperform Votes7250.70% Underperform Votes7049.30% Which has stronger earnings & valuation, MIST or IGMS? Milestone Pharmaceuticals has higher earnings, but lower revenue than IGM Biosciences. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Pharmaceuticals$1M98.66-$59.69M-$0.81-2.28IGM Biosciences$2.92M132.05-$246.42M-$3.64-1.78 Does the media prefer MIST or IGMS? In the previous week, IGM Biosciences had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 1 mentions for IGM Biosciences and 0 mentions for Milestone Pharmaceuticals. IGM Biosciences' average media sentiment score of 1.24 beat Milestone Pharmaceuticals' score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Milestone Pharmaceuticals Neutral IGM Biosciences Positive Is MIST or IGMS more profitable? Milestone Pharmaceuticals has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,534.03%. Milestone Pharmaceuticals' return on equity of -151.82% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -151.82% -49.85% IGM Biosciences -7,534.03%-155.42%-61.04% Which has more volatility and risk, MIST or IGMS? Milestone Pharmaceuticals has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. SummaryMilestone Pharmaceuticals beats IGM Biosciences on 11 of the 18 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.66M$6.69B$5.22B$9.25BDividend YieldN/A2.98%5.12%4.28%P/E Ratio-2.2810.6087.8017.22Price / Sales98.66204.011,161.56122.20Price / CashN/A57.1543.3837.82Price / Book3.705.154.834.93Net Income-$59.69M$151.58M$120.83M$225.51M7 Day Performance7.56%3.08%2.44%3.90%1 Month PerformanceN/A-4.25%17.51%1.68%1 Year Performance-7.04%7.42%28.57%16.09% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals1.7113 of 5 stars$1.89+2.2%$12.00+534.9%-35.8%$100.79M$1M-2.3330IGMSIGM Biosciences4.6324 of 5 stars$6.45-6.5%$17.75+175.2%-23.4%$383.54M$2.92M-1.77190CYRXCryoport3.409 of 5 stars$7.69-2.2%$12.29+59.8%-51.1%$380.12M$226.11M-2.281,170Short Interest ↓TSHATaysha Gene Therapies3.409 of 5 stars$1.83-1.1%$6.63+262.0%+13.5%$375.05M$9.92M2.90180Short Interest ↑CTNMContineum Therapeutics2.2526 of 5 stars$14.24+5.5%$29.25+105.4%N/A$367.08M$50M0.0031Short Interest ↓Gap DownRGNXREGENXBIO4.5028 of 5 stars$7.38-3.1%$35.27+378.0%-60.3%$365.64M$84.33M-1.47344Short Interest ↑GHRSGH Research1.5317 of 5 stars$7.01+2.3%$35.67+408.8%+29.1%$364.72MN/A-8.8710Gap UpYMABY-mAbs Therapeutics3.1362 of 5 stars$8.12-1.9%$20.89+157.3%+20.0%$363.69M$84.55M-15.04150SANASana Biotechnology1.9116 of 5 stars$1.62-2.1%$13.50+735.9%-60.0%$360.58MN/A-1.15328DSGNDesign Therapeutics1.0585 of 5 stars$6.22-0.5%$7.00+12.5%+137.8%$352.18MN/A-7.3240KMDAKamada3.9732 of 5 stars$6.04+2.4%$14.50+140.1%-0.7%$347.18M$158.38M21.57360Short Interest ↓Gap Up Related Companies and Tools Related Companies IGMS Alternatives CYRX Alternatives TSHA Alternatives CTNM Alternatives RGNX Alternatives GHRS Alternatives YMAB Alternatives SANA Alternatives DSGN Alternatives KMDA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MIST) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partnersliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredThe Key to Feeding 8.1 Billion PeopleImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
